$CRM 300c exp Jan 2025 is a low-risk bullish trade.Morgan Stanley's note on NYSE:CRM : Weak bookings in Q1 further test investor patience as the GenAI innovation cycle has yet to inflect top-line results and now increasingly becomes a point of competitive concern. However, the multiple does not reflect any GenAI expectations and actually under prices core EPS growth.